Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Interest & Investment Income (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Interest & Investment Income for 12 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest & Investment Income fell 5.97% year-over-year to $1.6 million, compared with a TTM value of $5.0 million through Sep 2025, down 40.16%, and an annual FY2024 reading of $7.1 million, down 27.46% over the prior year.
  • Interest & Investment Income was $1.6 million for Q3 2025 at CytomX Therapeutics, up from $1.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.7 million in Q3 2023 and bottomed at $44000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $1.2 million, with a median of $1.2 million recorded in 2025.
  • The sharpest move saw Interest & Investment Income crashed 93.67% in 2021, then soared 3322.06% in 2023.
  • Year by year, Interest & Investment Income stood at $73000.0 in 2021, then surged by 902.74% to $732000.0 in 2022, then soared by 241.94% to $2.5 million in 2023, then plummeted by 48.94% to $1.3 million in 2024, then rose by 24.57% to $1.6 million in 2025.
  • Business Quant data shows Interest & Investment Income for CTMX at $1.6 million in Q3 2025, $1.2 million in Q2 2025, and $955000.0 in Q1 2025.